Gerard Griffioen
Directeur Technique/Scientifique/R&D chez reMYND NV
Profil
Gerard Griffioen is currently the Chief Scientific Officer-Drug Discovery at reMYND NV.
He previously worked as a Principal at the University of Vienna and Katholieke Universiteit Leuven.
Dr. Griffioen obtained a doctorate degree from Vrije Universiteit Amsterdam in 1996.
Postes actifs de Gerard Griffioen
| Sociétés | Poste | Début |
|---|---|---|
reMYND NV
 reMYND NV Miscellaneous Commercial ServicesCommercial Services reMYND NV engages in the development of disease-modifying treatments against alzheimer's, parkinson's, diabetes and other protein misfolding disorders. Its drug and development unit focuses on innovative, disease-modifying drugs for treating degenerative disorders. The company was founded by Fred Van Leuven, Stefaan Wera and Joris Winderickx in 2002 and is headquartered in Leuven, Belgium. | Directeur Technique/Scientifique/R&D | - |
Anciens postes connus de Gerard Griffioen
| Sociétés | Poste | Fin |
|---|---|---|
| Katholieke Universiteit Leuven | Corporate Officer/Principal | - |
| University of Vienna | Corporate Officer/Principal | - |
Formation de Gerard Griffioen
| Vrije Universiteit Amsterdam | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
reMYND NV
reMYND NV Miscellaneous Commercial ServicesCommercial Services reMYND NV engages in the development of disease-modifying treatments against alzheimer's, parkinson's, diabetes and other protein misfolding disorders. Its drug and development unit focuses on innovative, disease-modifying drugs for treating degenerative disorders. The company was founded by Fred Van Leuven, Stefaan Wera and Joris Winderickx in 2002 and is headquartered in Leuven, Belgium. | Commercial Services |
